Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic vs. on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8:745–52.

Article  CAS  PubMed  Google Scholar 

Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. N Engl J Med. 2007;357:535–44.

Article  CAS  PubMed  Google Scholar 

Hay CR. Prophylaxis in adults with haemophilia. Haemophilia. 2007;13(Suppl 2):10–5.

Article  CAS  PubMed  Google Scholar 

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.

Article  PubMed  Google Scholar 

Hermans C, Mancuso ME, Nolan B, Pasi KJ. Recombinant factor VIII Fc for the treatment of haemophilia A. Eur J Haematol. 2021;106(6):745–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taki M, Fukutake K, Kobayashi M, Nagao A, Makioka H, Shiraishi M. Initial safety results from a prospective post-marketing surveillance study using rFVIIIFc in the real world setting in Japanese hemophilia A patients. Res Practice Thrombosis Haemostasis. 2017;1(Suppl1):738.

Google Scholar 

Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and rare coagulation disorders of the scientific and standardization committee of the international society on thrombosis and hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–9.

Article  CAS  PubMed  Google Scholar 

Chang CY, Li TY, Cheng SN, Pan RY, Wang HJ, Lin SY, et al. Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia. Haemophilia. 2017;23(2):284–91.

Article  PubMed  Google Scholar 

Chen YC, Chang CY, Cheng SN, Pan RY, Shih YL, Li TY, et al. Evolution of congenital haemophilia care in Taiwan. J Formos Med Assoc. 2021. https://doi.org/10.1016/j.jfma.2021.07.017.

Article  PubMed  PubMed Central  Google Scholar 

Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677–86.

Article  PubMed  PubMed Central  Google Scholar 

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016;22(1):72–80.

Article  CAS  PubMed  Google Scholar 

Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13(6):967–77.

Article  CAS  PubMed  Google Scholar 

Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia. 2018;24(3):414–9.

Article  CAS  PubMed  Google Scholar 

Giraud R, Delmotte N, Gensollen S, Roche M, Falaise C, Chambost H, et al. Recombinant factor VIII Fc fusion protein (rFVIIIFc) in real life: one-year clinical and economic outcomes. Drugs Real World Outcomes. 2021;8(4):527–35.

Article  PubMed  PubMed Central  Google Scholar 

Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Director’s Organisation. Haemophilia. 2020;26(3):529–35.

Article  PubMed  Google Scholar 

Wall C, Scott M, Xiang H, Palmer B, Collins P, Chowdary P, et al. Longitudinal Analysis of rFVIIIFc Use and Efficacy in the UK: A Report from the National Haemophilia Database [abstract]. Res Pract Thromb Haemost 2020;4 (Suppl 1). https://abstracts.isth.org/abstract/longitudinal-analysis-of-rfviiifc-use-and-efficacy-in-the-uk-a-report-from-the-national-haemophilia-database/. Accessed August 18, 2021

Holmström M, Olsson E, Astermark J, Axelsson M, Olsson A, Myrin Westesson L, et al. Real-world prophylactic usage of recombinant factor VIII Fc in Sweden: a report from the Swedish national registry for bleeding disorders. Haemophilia. 2021;27(4):e554–8.

Article  PubMed  Google Scholar 

Sun HL, Yang M, Poon MC, Lee A, Robinson KS, Sholzberg M, et al. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: a Canadian observational study of real-world outcomes. Haemophilia. 2021;27(5):751–9.

Article  PubMed  Google Scholar 

Tagliaferri A, Matichecchia A, Rivolta GF, Riccardi F, Quintavalle G, Benegiamo A, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfus. 2020;18(5):374–85.

PubMed  PubMed Central  Google Scholar 

Ay C, Feistritzer C, Rettl J, Schuster G, Vavrovsky A, Perschy L, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021;11:12967.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648–54.

Article  CAS  PubMed  Google Scholar 

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–64.

Article  CAS  PubMed  Google Scholar